Baidu
map

中国前列腺癌数据库 C-CAP 将正式启用

2014-12-24 MedSci MedSci原创

前列腺癌是全球第二大男性恶性肿瘤,既往在我国发生率较低,但人口老龄化和生活方式改变使我国前列腺癌的发病率急剧上升,已跃居男性恶性肿瘤的第六位 ,成为泌尿外科中发病率最高的肿瘤。抽样调查显示,上海、北京和广州的发病率分别为 32.2/10 万、19.3/10 万和 17.57/10 万 。20 年间我国前列腺癌发病率增长了 10 余倍。 前列腺癌不仅给患者家庭,也给国民经济发展带来了沉重的负担。

前列腺癌是全球第二大男性恶性肿瘤,既往在我国发生率较低,但人口老龄化和生活方式改变使我国前列腺癌的发病率急剧上升,已跃居男性恶性肿瘤的第六位 ,成为泌尿外科中发病率最高的肿瘤。抽样调查显示,上海、北京和广州的发病率分别为 32.2/10 万、19.3/10 万和 17.57/10 万 。20 年间我国前列腺癌发病率增长了 10 余倍。 前列腺癌不仅给患者家庭,也给国民经济发展带来了沉重的负担。

北京, 2014 年 12 月 21 日——吴阶平医学基金会泌尿外科学部宣布中国首个前列腺癌领域数据库“中国前列腺癌数据库(C-CAP)”将于 2015 年 1 月 1 日正式启用。该数据库的建立得到国家卫生和计划生育委员会、国家疾病控制预防中心、国家肿瘤防治办公室、中华医学会泌尿外科学分会各省主任委员的重视与支持。中国抗癌协会泌尿男性生殖系肿瘤专业委员会主任委员、中国前列腺癌诊断与治疗指南编写专家组组长那彦群教授表示:“通过收集和管理中国前列腺癌患者的诊断、治疗和随访数据,充分了解中国前列腺癌发生、发展的规律将助力提升我国前列腺癌的治疗效果,提升临床诊疗规范化,同时也为国家经济发展,为国家制定疾病诊疗经济宏观调控提供依据。”

中国前列腺癌数据库已完成系统搭建并正在开展试运行。目前,全国范围内有 32 家医院正在通过网络向数据库传输数据,其中首批参与测试的 13 家医院已完成部分患者数据录入。数据库正式启用后,加入该数据库医院的相关医生可直接登陆数据库网站或手机客户端,简便且快速地创建、随访、查看、分析和导出其所在医院的患者数据,追踪并更新所负责患者的治疗方案。卫生部北京医院泌尿外科主任医师, 中国前列腺癌诊断与治疗指南编写专家组委员朱刚教授指出:“中国前列腺癌数据库不仅能实现医师和医院对前列腺癌患者诊疗数据进行智能化管理、提升诊疗效率,还能通过手机用户端的随访提醒、用药提醒、患者教育等功能帮助到每一位患者” 

中国前列腺癌数据库借鉴了 1995 年建立的美国前列腺癌数据库(CaPSURETM)、2001 年建立的日本前列腺癌数据库(J-CAP)和 2011 年建立的韩国前列腺癌数据库(K-CAP)的成功经验。武田(中国)投资有限公司总裁卢安邦表示:“中国前列腺癌数据库的建立将有益于中国实现与其它国家长期开展前列腺癌治疗的学术交流与联合发展。武田凭借在不同国家获得的相关经验,将继续支持亚洲国家在前列腺癌治疗领域的联合发展,辅助中、日、韩三国的前列腺癌数据库联合成亚洲前列腺癌数据库(A-CAP),帮助更多前列腺癌患者的有效治疗。”

关于吴阶平基金会

吴阶平医学基金会经中华人民共和国卫生部、民政部批准于 2002 年 2 月 28 日在北京成立,是卫计委主管、民政部批准设立的行业基金会。 终身名誉会长为吴阶平院士,名誉会长为全国政协副主席、中国科学技术协会主席、九三学社中央主席韩启德院士。理事长为晓萌女士。

吴阶平医学基金会的宗旨是联合国内外关心医学和健康事业发展的人士,筹募资金,通过奖励和资助各项学术活动等,颂扬吴阶平院士的高尚医德和治学精神,为促进医药卫生事业的发展而共同奋斗。吴阶平医学基金会成立以来,在激励广大医师提高专业水平、支持医学科研和医学领域的学术交流、组织各学科的继续教育及专科培训、开展健康公益活动和科普教育、设立临床研究专项基金用于支持临床医师的科研工作及临床用药的安全指导,针对有关临床药物进行论证和应用培训、参与支持中医药的开发和研制等方面积极开展工作,为促进医学和健康事业的发展做出努力。吴阶平医学基金会泌尿外科学部成立于 2012 年。吴阶平院士是新中国泌尿外科事业的奠基人、中华医学会泌尿外科学分会创始人、中华泌尿外科杂志的创办人、泌尿外科专家。吴阶平医学奖泌尿外科学奖是中国泌尿外科界的最高奖项,吴阶平医学基金会为中国广大泌尿外科医生所熟悉。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2022-07-23 1540564381

    官网在哪里呢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-05-21 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-04-07 wang866

    支持大数据库

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-01-21 catchyufish

    前列腺癌联盟

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-01-21 catchyufish

    前列腺癌联盟

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-01-10 zczcz6655

    新的观点新的想法

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2014-12-27 effie554

    早就该有了,一直期盼的数据库啊

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1234124, encodeId=3714123412454, content=官网在哪里呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9dd84960159, createdName=1540564381, createdTime=Sat Jul 23 02:19:34 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897969, encodeId=f20e189e96978, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu May 21 07:32:00 CST 2015, time=2015-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19897, encodeId=af0b1989e61, content=支持大数据库, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=209274531, createdName=wang866, createdTime=Tue Apr 07 18:59:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14570, encodeId=9f50145e0bd, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:51:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14569, encodeId=14fe145691b, content=前列腺癌联盟, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c901612346, createdName=catchyufish, createdTime=Wed Jan 21 22:48:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13947, encodeId=b9e21394eba, content=新的观点新的想法, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/27/fbd784adc68b967ee1f6d8d7192692c0.jpg, createdBy=771884322, createdName=zczcz6655, createdTime=Sat Jan 10 21:29:00 CST 2015, time=2015-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13509, encodeId=2cd113509e3, content=早就该有了,一直期盼的数据库啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=068c1609904, createdName=effie554, createdTime=Sat Dec 27 19:56:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13438, encodeId=ed6c1343811, content=这是大趋势呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=116.231.235.162, createdTime=Wed Dec 24 14:36:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2014-12-24 116.231.235.162

    这是大趋势呀

    0

相关资讯

JCO:低风险前列腺癌长期随访监测安全可行

加拿大多伦多大学新宁医院的Laurence Klot等人12月15日在线发表在临床肿瘤学杂志(journal of clinical oncology,JCO)上的一项究显示,对低风险的前列腺癌患者进行为期15年的随访监测是安全可行的。 在此项前瞻性单臂队列单中心研究中,共纳入993例低度、中度风险的前列腺癌患者,对前列腺特异抗原(PSA)倍增时间不足3年、格里森(

JCO:2014 年前列腺癌切除术后辅助和挽救性放疗指南

近日,美国临床肿瘤学会 (ASCO) 完成了对美国泌尿协会(AUA)/ 美国放射肿瘤学会 (ASTRO) 关于前列腺癌术后辅助性及挽救性放疗指南的背书程序。该指南发表于 JCO 杂志上。该前列腺切除术后辅助和挽救性放疗指南是基于医学文献的系统性回顾制定的。ASCO 背书小组对该指南进行了内容和建议的审查工作。在西方国家中,前列腺癌是男性中发病率最高的肿瘤。根治性手术和放射治疗是局限期前列腺癌最重要

Cancer Epidem Biomar:适度运动有利降低前列腺癌死亡率

根据一项发表在Cancer Epidemiology, Biomarkers & Prevention杂志上的新研究证实:适度的体力活动会减少并尚未扩散的前列腺癌男性患者死亡率,这行研究结果将鼓励专家在更大的临床实验中进一步确认上述相关性。 该研究调查了4,623名瑞典人,这些人在1997年和2002年之间被诊断为局限性前列腺癌,并且一直追访研究他们直到2012年。他们完成了运动水平的问

J Urol:睾酮疗法与前列腺癌无关联

长期以来睾酮疗法通常用于治疗男性的性功能减退,尽管没有证据显示睾酮疗法可以增加男性个体患前列腺癌的风险,但仍有很多研究人员对这一课题展开了很多研究,近日,一篇发表于国际杂志The Journal of Urology上的研究论文中,来自德国的研究人员对超过1000名个体进行了三组平行研究,分析揭示了长期的睾酮疗法是否安全以及其是否会增加个体患前列腺癌的风险。 泌尿学家Ahmad Haider

Cancer Res:艾滋病药物对抗前列腺癌!

尽管前列腺癌在很多男性中都可以被成功治愈,但是当癌症转移到患者骨头中就对患者是致命性的影响,近日,发表在国际杂志Cancer Research上的一篇研究论文中,来自托马斯杰斐逊大学的研究人员揭示了,在HIV疗法中扮演重要角色的受体CCR5或许可以驱动前列腺癌向骨头中的转移。 医学博士Richard Pestell表示,本文研究我们在临床前模型中可以有效减少癌症的转移,我们在于揭示是否用于H

重磅!强生Zytiga霸主地位不保,安斯泰来前列腺癌药物Xtandi拿下欧美2大市场

安斯泰来(Astellas)和Medivation合作研发的新一代前列腺癌口服药物Xtandi(enzalutamide)监管方面爆出大好消息。继今年9月FDA批准Xtandi用于前列腺癌化疗前治疗,近日欧盟也已批准Xtandi用于化疗前治疗。尽管强生(JNJ)新一代前列腺癌口服药物Zytiga早在2011年4月上市之后一直统治市场,但Xtandi具有单独用药的独特优势,业界预测,在欧美2大主要市

Baidu
map
Baidu
map
Baidu
map